Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid-core-peptides

Immunology and Cell Biology

Volumn 82, Issue 5, 2004, Pages 517-522

  White, Karen ^a   Kearns, Philip ^b   Toth, Istvan ^b   Hook, Sarah ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

CD8 T cell; Lipid core peptide; Tumour; Vaccine

Indexed keywords

EPITOPE; IMMUNOLOGICAL ADJUVANT; LIPID CORE PEPTIDE; LYSINE; PEPTIDE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CYTOTOXIC T LYMPHOCYTE; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; LIPOPROTEINS; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; OVALBUMIN; PEPTIDE FRAGMENTS; POLYLYSINE;

ANIMALIA;

EID: 7044249878     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0818-9641.2004.01269.x     Document Type: Article

References (33)

1. Arnon R. Synthetic peptides as the basis for vaccine design. Mol. Immunol. 1991; 28: 209-15.
2. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2002; 2: 425-31.
3. Janeway Jr CA, Medzhitov R. Innate Immune Recognition. Ann. Rev. Immunol. 2002; 20: 197-216.
4. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol. 2001; 2: 675-80.
5. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003; 21: 685-711.
6. Singh M, O'Hagan DT. Recent advances in vaccine adjuvants. Pharm. Res. 2002; 19: 715-28.
7. Hovarth A, Olive C, Wong A et al. Lipoamino acid-based adjuvant carrier system: Enhanced immunogenicity of Group A Streptococcal peptide epitopes. J. Med. Chem. 2002; 45: 1387-90.
8. Fonseca PAJ, Joosten D, Snippe H, Verheul AFM. Evaluation of T-cell responses to peptides and lipopeptides with MHC class I binding motifs derived from the amino acid sequence of the 19-kDa lipoprotein of Mycobacterium tuberculosis. Mol. Immunol. 2000; 37: 413-22.
9. Hertz CJ, Kiertscher SM, Godowski PJ et al. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J. Immunol. 2001; 166: 2444-50.
10. Loing E, Delanoye A, Sergheraert C, Tartar A, Gras-Masse H. Assessing delivery of lipopeptides into the cytoplasm of intact cells by a functional assay based on PKC inhibition. I. The Jurkat model. Peptide Res. 1996; 9: 229-32.
11. Toth I, Danton N, Flinn N, Gibbons WA. A combined adjuvant and carrier system for enhancing synthetic peptides immunogenicity utilising lipidic amino acids. Tetrahedron Lett. 1993; 34: 3925-8.
12. Olive C, Batzloff M, Horvath A et al. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect. Immun. 2003; 71: 2373-83.
13. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 1996; 17: 131-7.
14. Carbone FR, Kurts C, Bennett SRM, Miller JFA, Heath WR. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol. Today 1998; 19: 368-73.
15. Hayman WA, Toth I, Flinn N, Scanlon M, Good MF. Enhancing the immunogenicity and modulating the fine epiptope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol. Cell Biol. 2002; 80: 178-87.
16. Olive C, Baltzloff MR, Horvath A et al. A lipid core peptide construct containing a conserved region determinant of the Group A streptococcal M protein elicits heterologous opsonic antibodies. Infect. Immun. 2002; 70: 2734-8.
17. Gibbons AW, Hughes RA, Szeto A et al. Lipidic Peptides I. Synthesis resolution and structural elucidation of fatty amino acids and their homo- and hetero-oligomers. Liebigs Ann. Chem. 1990: 1175-83.
18. Schnölzer M, Alewood P, Jones A, Alewood D, Kent SBH. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Int. J. Peptide Protein Res. 1992; 40: 180-93.
19. Stewart JM, Young JD. Solid Phase Peptide Synthesis. Rockford, IL: Pierce Chemical Company, 1984.
20. Ritchie DS, Hermans IF, Lumsden JM et al. Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J. Immunol. Meth. 2000; 246: 109-17.
21. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54: 777-85.
22. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol. 2002; 169: 4905-12.
23. Moody DB, Eriken V, Cheng T-Y et al. Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat. Immunol. 2002; 3: 435-42.
24. Michelsen KS, Aicher A, Mohaupt M et al. The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCs). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J. Biol. Chem. 2001; 276: 25680-6.
25. Thoma-Uszynski S, Kiertscher SM, Ochoa MT et al. Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10. J. Immunol. 2000; 165: 3804-10.
26. Schjetne KW, Thompson KM, Nilsen N et al. Link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J. Immunol. 2003; 171: 32-6.
27. Sittelaar KJ, Hoogerhout P, Ovaa W et al. In vitro processing and presentation of a lipidated cytotoxic T-cell epitope derived from measles virus fusion protein. Vaccine 2002; 20: 249-61.
28. Toes REM, Blom RJJ, Offringa R, Kast WM, Melief CJM. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 1996; 156: 3911-8.
29. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 1998; 188: 2199-204.
30. Bourgeois C, Tanchot C. Minireview CD4 T cells are required for CD8 T cell memory generation. Eur. J. Immunol. 2003; 33: 3325-31.
31. Martinez X, Regner M, Kovarik J et al. CD4-independent protective cytotoxic T cells induced in early life by a non-replicative delivery system based on virus-like particles. Virology 2003; 305: 428-35.
32. Bour H, Horvath C, Lurquin C, Cerottini JC, MacDonald HR, Ishii KJ. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization. J. Immunol. 1998; 160: 5522-9.
33. Zhan Y, Corbett AJ, Brady JL, Sutherland RM, Lew AM. CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation. J. Immunol. 2000; 165: 3612-9.